ASCO News In Brief: Hoechst Marion Roussel Anzemet
Hoechst Marion Roussel Anzemet: Oral dolasetron mesylate for prevention of acute nausea and vomiting after moderately emetogenic platinum-containing chemotherapy may be optimal at 200 mg dose, according to dose-response data from a 307-patient trial presented at the American Society of Clinical Oncology meeting in Philadelphia May 18-21. The drug is administered 30 minutes prior to chemotherapy. A complete response rate of 73% was reported in the 200 mg dolasetron arm, compared to a 40% CR in the 25 mg arm; 61% of patients receiving 200 mg had no nausea versus 35% of those receiving 25 mg. An NDA for Anzemet was submitted in April...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth